Safety of sublingual immunotherapy in children

Expert Opinion on Drug Safety

Volumn 13, Issue 7, 2014, Pages 947-953

  Frati, Franco ^a   Ridolo, Erminia ^b   Fuiano, Nicola ^c   Barberi, Salvatore ^d   Dell'Albani, Ilaria ^a   Landi, Massimo ^e   Ricciardi, Luisa ^f   Scala, Guglielmo ^g   Incorvaia, Cristoforo ^h  

^a Scientific Department Stallergenes   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c Paediatric Allergy Service   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e ASL TO 1   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

^g Loreto Crispi Hospital   (Italy)

^h ICP Hospital   (Italy)

Author keywords

Children; Major allergen; Safety; Sublingual immunotherapy

Indexed keywords

ALLERGEN; BETAMETHASONE; CHLORPHENIRAMINE; POLLEN ANTIGEN; POLLEN EXTRACT;

ABDOMINAL PAIN; ALLERGIC ASTHMA; ALLERGY; ANAPHYLAXIS; ATOPIC DERMATITIS; BURNING SENSATION; CHILDHOOD DISEASE; COUGHING; DIARRHEA; DRUG MEGADOSE; DRUG SAFETY; FOOD ALLERGY; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; RHINORRHEA; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC ANAPHYLAXIS; TONGUE SWELLING; URTICARIA; CHEMICALLY INDUCED; CHILD; HYPERSENSITIVITY; RISK FACTOR; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ANAPHYLAXIS; CHILD; HUMANS; HYPERSENSITIVITY; RISK FACTORS; SUBLINGUAL IMMUNOTHERAPY;

EID: 84902689489     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.918949     Document Type: Review

References (51)

1. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO Position Paper. J Allergy Clin Immunol 1998;102:558-62
2. Committee on Safety in Medicine. CSM update: desensitizing vaccines. BMJ 1986;293:948
3. Lockey RF, Benedikt LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987;79:660-77
4. Scadding G, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986;16:483-91
5. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:4-12
6. Radulovic S, Wilson DE, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011;66:740-52
7. Gidaro GB, Marcucci F, Sensi L, et al. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005;35:565-71
8. Eifan AO, Keles S, Bahceciler NN. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007;62:567-8
9. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008;63:374
10. Rodriguez-Perez N, Ambriz-Moreno J, Canonica GW, et al. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol 2008;101:304-10
11. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009;64:963-4
12. Calderon MA, Simons FER, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67:303-11
13. Di Rienzo V, Pagani A, Parmiani S, et al. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999;54:1110-13
14. Cox L. Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations. Curr Allergy Asthma Rep 2007;7:410-20
15. Passalacqua G, Guerra L, Compalati E, Canonica GW. The safety of allergen specific sublingual immunotherapy. Curr Drug Saf 2007;2:117-23
16. Marcucci F, Sensi L, Incorvaia C, et al. Oral reactions to sublingual immunotherapy: a bioptic study. Allergy 2007;62:1475-7
17. Di Rienzo V, Minelli M, Musarra A, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005;35:560-4
18. Agostinis F, Tellarini L, Falagiani P, et al. Safety of SLIT with a monomeric allergoid in very young children. Allergy 2005;60:133
19. Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005;95:254-8
20. Rodriguez Santos O. Sublingual immunotherapy in allergic rhinitis and asthma in 2-5 year-old children sensitized to mites. Rev Alerg Mex 2008;55:71-5
21. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy world allergy organization position paper 2009. Allergy 2009;64(Suppl 91):1-59
22. Rossi RE, Monasterolo G. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 2005;18:277-85
23. Tripodi S, Di Rienzo Businco A, Benincori A, et al. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol 2006;139:149-32
24. Stelmach I, Kaczmarek-Wozniak J, Majak P, et al. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy 2009;39:401-8
25. Seidenberg J, Pajno GB, Bauer CP, et al. Safety and tolerability of seasonal, ultra-rush, high dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents. J Invest Allergol Clin Immunol 2009;19:125-31
26. Ariano R, Incorvaia C, La Grutta S, et al. Safety of sublingual immunotherapy started during the pollen season. Curr Med Res Opin 2009;25:103-7
27. Mosges R, Graute V, Christ H, et al. Safety of ultra-rush titration of sublingual immunotherapy in asthmatic children with tree-pollen allergy. Pediatr Allergy Immunol 2010;21:1135-8
28. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45
29. Wahn U, Tabar A, Kuna P, et al. SLIT Study Group. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160-6
30. Halken S, Agertoft L, Seidenberg J, et al. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol 2010;21:970-6
31. Ciprandi G, Cadario G, Di Gioacchino GM, et al. Sublingual immunotherapy in children with allergic polysensitization. Allergy Asthma Proc 2010;31(3):227-31
32. Gupta RS, Springston EE, Warrier MR, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics 2011;128:9-17
33. Oppenheimer H, Nelson HS, Bock AS, et al. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992;90:256-62
34. Nurmatov U, Venderbosch I, Devereux G, et al. Allergen-specific oral immunotherapy for peanut allergy. Cochrane Database Syst Rev 2012;9:CD009014
35. Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 2011;127:654-60
36. Kim EH, Bird JA, Kulis M, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 2011;127:640-6
37. Fleischer DM, Burks AW, Vickery BP, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol 2013;131:119-27
38. Wang J, Sampson HA. Oral and sublingual immunotherapy for food allergy. Asian Pac J Allergy Clin Immunol 2013;31:198-209
39. de Boissieu D, Dupont C. Sublingual immunotherapy for cow's milk protein allergy: a preliminary report. Allergy 2006;61:1238-9
40. Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol 2012;129:448-55
41. Incorvaia C. Preventive capacity of allergen immunotherapy on the natural history of allergy. J Prev Med Hyg 2013;54:71-4
42. Bae JM, Choi YY, Park CO, et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2013;132:110-17
43. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007;120:164-70
44. Tabar AI, Anda M, Bonifazi F, et al. Specific immunotherapy with standardized latex extracts versus placebo in latex-allergic patients. Int Arch Allergy Immunol 2006;141:369-76
45. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006;61:1236-7
46. Bernardini R, Campodonico P, Burastero S, et al. Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study. Curr Med Res Opin 2006;22:1515-22
47. Nettis E, Delle Donne P, Di Leo E, et al. Latex immunotherapy: state of the art. Ann Allergy Asthma Immunol 2012;109:160-5
48. Incorvaia C, Frati F. One century of allergen-specific immunotherapy for respiratory allergy. Immunotherapy 2011;3:629-35
49. Epstein TG, Liss GM, Murphy-Berendts K, et al. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract 2014;2:161-7
50. Incorvaia C, Frati F, Dell'Albani I, et al. Safety of hymenoptera venom immunotherapy: a systematic review. Expert Opin Pharmacother 2011;12:2527-32
51. Johansen P, von Moos S, Monahan D, et al. New routes for allergen immunotherapy. Hum Vaccin Immunother 2012;8:1525-33